Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers examined Baricitinib's role as a treatment for Alopecia Areata, contrasting it with conventional therapies, and found that while effective, Baricitinib may cause adverse reactions depending on individual patient health histories.

This study found that baricitinib significantly reduced hair loss in patients with severe alopecia areata, decreasing the mean SALT score from 96.6 to 48 over 24 weeks, with no patients dropping out and only mild adverse events in 12.7% of participants.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.

Hair follicles are crucial for maintaining skin barrier function.

This study discusses that many patients experience temporary hair loss after bariatric surgery, potentially due to rapid weight loss, surgery stress, and nutritional deficiencies, including shortages of iron, zinc, and other nutrients crucial for hair health.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

In this report, a 58-year-old woman with ocular myasthenia gravis experienced complete resolution of symptoms and hair regrowth after six months of treatment with the JAK inhibitor baricitinib, highlighting a potential new therapeutic approach for this condition.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

In this case report, an 8-year-old with severe alopecia areata and atopic dermatitis experienced significant hair regrowth and improved dermatitis symptoms after treatment with dupilumab followed by baricitinib, with no major side effects observed.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

In this study, baricitinib was used as monotherapy to treat a 21-year-old woman with severe alopecia areata, resulting in significant hair regrowth and reduced alopecia severity within three months, suggesting its effectiveness and potential as a robust treatment option for this condition.

In this case report, a 40-year-old male with alopecia universalis and twenty-nail dystrophy showed significant nail improvement and partial hair regrowth after six months of baricitinib treatment, improving his quality of life.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

This case report highlights the successful treatment of alopecia areata universalis with Baricitinib, suggesting potential long-term effectiveness of janus kinase inhibitors for this autoimmune hair loss condition.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

In this case report, a patient with alopecia areata-associated nail changes experienced normalization of nail appearance and texture after 11 months of treatment with baricitinib, suggesting that the drug may be an effective option for similar cases, although further research is needed.

In this case report, the authors describe the first documented occurrence of new-onset hypocortisolism after laparoscopic sleeve gastrectomy in a patient, highlighting the need for awareness of this condition among clinicians when patients present with nonspecific symptoms post-bariatric surgery.

In this report, a young Caucasian woman developed a hairy tongue as an unusual side effect during baricitinib therapy for severe alopecia areata, which was managed by daily toothbrush debridement.

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.